D. Rusnak

发表

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.

Hieu T. Do, Meenhard Herlyn, David M. Wilson, 2006, Cancer research.

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.

P. A. Harris, L. Kuyper, S. Frye, 2001, Journal of medicinal chemistry.

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.

M. Berger, M. Untch, R. Finn, 2006, Cancer research.

Altered Growth Factor Dependence and Transforming Growth Factor Gene Expression in Transformed Rat Tracheal Epithelial Cells

C. Walker, P. Nettesheim, H. Earp, 1989, Molecular carcinogenesis.

Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines

Joel Greshock, Richard Wooster, R. Wooster, 2008, Molecular Cancer Therapeutics.

Epidermal growth factor dependence and TGFα autocrine growth regulation in primary rat tracheal epithelial cells

P. Nettesheim, A. Robertson, D. Rusnak, 1992 .

Eltrombopag, but Not Romiplostim or Thrombopoietin, Inhibits Growth of Thrombopoietin Receptor Positive and Negative Human Leukemia Cell Lines

S. K. Rudolph, C. Erickson-Miller, D. Rusnak, 2012 .

Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580.

J. Parham, L. Frick, R. Crosby, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Synthesis and evaluation of aniline headgroups for alkynyl thienopyrimidine dual EGFR/ErbB-2 kinase inhibitors.

A. Waterson, R. Griffin, K. Hinkle, 2009, Bioorganic & medicinal chemistry letters.

Synthesis and stereochemical effects of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines as EGFR and ErbB-2 inhibitors.

A. Waterson, R. Griffin, D. Uehling, 2009, Bioorganic & medicinal chemistry letters.

Dual EGFR/ErbB-2 inhibitors from novel pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidines.

A. Waterson, R. Griffin, D. Uehling, 2008, Bioorganic & medicinal chemistry letters.

A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)

Krystal J Alligood, Karen Lackey, K. Lackey, 2004, Cancer Research.

6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases

Edgar R. Wood, Robert J. Griffin, Michael J. Reno, 2008, Proceedings of the National Academy of Sciences.

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series.

K. Lackey, R. Mook, A. Walker, 2006, Bioorganic & medicinal chemistry letters.

The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.

K. Lackey, T. Gilmer, E. Wood, 2001, Molecular cancer therapeutics.

Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb®, GW572016) in an expanded panel of human normal and tumour cell lines

A. Martin, T. Gilmer, S. K. Rudolph, 2007, Cell proliferation.

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

Hong Ma, Krystal J Alligood, G. Owens, 2002, Oncogene.

The formation of a covalent complex between a dipeptide ligand and the src SH2 domain.

P. Charifson, L. Shewchuk, W. Rocque, 1998, Bioorganic & medicinal chemistry letters.

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.

L. Shewchuk, T. Gilmer, A. Truesdale, 2008, Cancer research.

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles

P. Hegde, T. Gilmer, J. Strum, 2007, Molecular Cancer Therapeutics.

The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

K. Lackey, T. Gilmer, R. Crosby, 2001, Cancer research.

Thienopyrimidine-based dual EGFR/ErbB-2 inhibitors.

D. Vanderwall, L. Shewchuk, A. Goetz, 2009, Bioorganic & medicinal chemistry letters.

Breast Cancer Cells against HER-2-Overexpressing and Trastuzumab-Treated Activity of the Dual Kinase Inhibitor Lapatinib ( GW 572016 )

M. Berger, M. Untch, R. Finn, 2006 .

Alterations in the localization of F-actin, fibronectin, and thrombospondin occur prior to neoplastic transformation in rat tracheal epithelial cells.

P. Nettesheim, C. A. Carter, D. Rusnak, 1994, Experimental cell research.

A simple method for predicting serum protein binding of compounds from IC(50) shift analysis for in vitro assays.

T. Gilmer, R. Copeland, T. J. Lansing, 2004, Bioorganic & medicinal chemistry letters.

The production and characterization of murine monoclonal antibodies to human Gadd45 raised against a recombinant protein.

A. Fornace, B. Champion, M. Kastan, 1995, Hybridoma.

Peptide inhibitors of src SH3-SH2-phosphoprotein interactions.

Larry J. Shampine, Patel, P. Charifson, 1995, The Journal of biological chemistry.

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolylquinazolines.

K. Lackey, T. Gilmer, R. Griffin, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and SAR of potent EGFR/erbB2 dual inhibitors.

Karen Lackey, K. Lackey, D. Vanderwall, 2004, Bioorganic & medicinal chemistry letters.